Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myeloid, Acute 1Dendritic Cell Sarcoma, Interdigitating 1Acromesomelic dysplasia, Maroteaux type 1

Interventions

Rituximab 21Cyclophosphamide 15Etoposide 11Vincristine 9Prednisone 9Doxorubicin 8Cytarabine 8Filgrastim 7Radiotherapy 6Peripheral Blood Stem Cell Transplantation 6fludarabine phosphate 5Melphalan 5Dexamethasone 4Carmustine 4Bendamustine Hydrochloride 4loncastuximab tesirine 3ibrutinib 3Tacrolimus 3Stem Cell Transplantation 3Mycophenolic Acid 3Methotrexate 3Gemcitabine 3Calcium Dobesilate 3CT-P10 3Busulfan 3venetoclax 2sargramostim 2polatuzumab vedotin 2pembrolizumab 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, Large B-Cell, Diffuse × pevonedistat × Clear all
NCT01415765 2019-12-17

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
LymphoidSarcoma

Acromesomelic dysplasia, Maroteaux type, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡